Valiant Laboratories' Q2 FY 2026-27 Quarterly Results
- 03 Nov 2026
Result Summary
- Valiant Laboratories Ltd reported a 0.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 148.3%.
- Its expenses for the quarter were up by 29.2% QoQ and 148.4% YoY.
- The net profit decreased 98.1% QoQ and increased 105.0% YoY.
- The earnings per share (EPS) of Valiant Laboratories Ltd stood at 0.08 during Q2 FY 2026-27.
Financial Statments for Q2 FY 2026-27
(₹ crores) | Q2FY27 | Q1FY27 | Q2FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 116.89 | 116.15 | 47.07 | 0.6% | 148.3% |
Total Expenses | 116.22 | 89.96 | 46.79 | 29.2% | 148.4% |
Profit Before Tax | 0.67 | 26.19 | 0.28 | -97.4% | 139.3% |
Tax | 0.26 | 5.09 | 0.08 | -94.9% | 225.0% |
Profit After Tax | 0.41 | 21.10 | 0.20 | -98.1% | 105.0% |
Earnings Per Share | 0.08 | 3.89 | 0.04 | -97.9% | 100.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Valiant Laboratories Ltd is a company whose primary business activities include the manufacturing and distribution of pharmaceutical products. The company operates within the pharmaceutical industry, engaging in the production of a range of healthcare solutions. As of the latest updates, there have been no major developments specific to Valiant Laboratories Ltd that have been made available. The company continues to focus on its core operations within the pharmaceutical sector, providing essential products and services to its customer base.
Revenue
In the second quarter of the fiscal year 2027 (Q2FY27), Valiant Laboratories Ltd reported a total income of ₹116.89 crores. This marks a marginal quarter-over-quarter (QoQ) increase of 0.6% from ₹116.15 crores in the first quarter of fiscal year 2027 (Q1FY27). Compared to the same quarter in the previous year (Q2FY26), where the total income was ₹47.07 crores, the company experienced a significant year-over-year (YoY) increase of 148.3%. This substantial YoY growth reflects the company's enhanced revenue generation capabilities over the past year.
Profitability
The profitability metrics for Valiant Laboratories Ltd in Q2FY27 indicate significant changes compared to both the previous quarter and the same quarter last year. Profit Before Tax (PBT) was ₹0.67 crores, showing a sharp decline of 97.4% QoQ from ₹26.19 crores in Q1FY27. On a YoY basis, PBT increased by 139.3% from ₹0.28 crores in Q2FY26. Tax expenses for the quarter stood at ₹0.26 crores, which is a decrease of 94.9% QoQ from ₹5.09 crores in Q1FY27, and an increase of 225.0% YoY from ₹0.08 crores in Q2FY26. The Profit After Tax (PAT) was ₹0.41 crores, marking a drastic QoQ decline of 98.1% from ₹21.10 crores in Q1FY27, but a YoY increase of 105.0% from ₹0.20 crores in Q2FY26. Earnings Per Share (EPS) for the quarter was ₹0.08, which decreased by 97.9% QoQ from ₹3.89, and increased by 100.0% YoY from ₹0.04.
Operating Metrics
The operating metrics of Valiant Laboratories Ltd for Q2FY27 reveal a total expenses amount of ₹116.22 crores. This represents a 29.2% increase QoQ from ₹89.96 crores in Q1FY27. Compared to Q2FY26, where total expenses were ₹46.79 crores, there is a YoY increase of 148.4%. The analysis of these financial metrics shows that despite the significant increase in total income YoY, the increase in expenses has impacted the overall profitability. These financial results highlight the dynamic nature of Valiant Laboratories Ltd's operational environment over the last few quarters.
FAQs
Valiant Laboratories Ltd announced its Q2 FY 2026-27 results on 3 November, 2026.
Valiant Laboratories Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Valiant Laboratories Ltd Q2 FY 2026-27 results include:
- Revenue: ₹116.89 crore
- Net Profit: ₹0.41 crore
- EBITDA: ₹5.28 crore
- Year-over-Year Growth: 148.3%
- Quarter-over-Quarter Growth: 0.6%
Valiant Laboratories Ltd reported a net loss of ₹0.41 crore in Q2 FY 2026-27, reflecting a 105.0% year-over-year growth.
Valiant Laboratories Ltd posted a revenue of ₹116.89 crore in Q2 FY 2026-27.